A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
100
Participants
Timeline
Start Date
September 30, 2024
Primary Completion Date
December 30, 2027
Study Completion Date
June 30, 2028
Conditions
Advanced Solid Tumors
Interventions
DRUG
HRS-4508
HRS-4508
Trial Locations (1)
100021
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
All Listed Sponsors
lead
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
NCT06598735 - A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter